← Browse by Condition
Medical Condition

adjuvant treatment

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 3
NCT07010419 Phase 3
Recruiting

A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）

Enrollment
338 pts
Location
China
Sponsor
Allist Pharmaceuticals, Inc.
View Trial →